Stay updated with breaking news from Peter Lebowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S....
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today...
Teclistamab, an off-the-shelf (ready to use) subcutaneously administered therapy, induced deep and rapid responses in triple-class exposed patients with relapsed and refractory multiple myeloma1 The
Teclistamab is the first T-cell redirecting bispecific antibody to receive a positive CHMP opinion for adults with RRMM and highlights Janssen's commitment to innovation in multiple myeloma The
Johnson & Johnson (JNJ) is in negotiations with two Chinese biotech companies for partnerships, The Financial Times reported Sunday, citing a senior executive of the U.S. pharma giant